McKesson（MCK）FY2025年报排雷报告

框架：唐朝《手把手教你读财报》+ Schilit《Financial Shenanigans》+ Beneish M-Score

核心理念："财报是用来排除企业的"

数据来源：SEC EDGAR 10-K原文 + Yahoo Finance

✅ 评级A——财务健康状况强劲

一句话：McKesson拿到A评级，通过了18项检查中的17项——唯一标记是现金对债务（77%覆盖率）的关注项，对运行营运资本密集模式的药品分销商来说是典型的。营收增长16.2%到$3,590.5亿，归属于McKesson的净利润增长10%到$32.95亿，FCF达$52.3亿，M-Score -2.48舒适位于安全区。分销模式产出3.71%的毛利率——设计就是薄如剃刀——但现金转换（CFFO/NI = 1.85）和债务/EBITDA 1.4x显示业务产生真实现金。负的报告股东权益（$-20.7亿）是回购的直接后果，不是运营恶化。Deloitte唯一的关键审计事项是与阿片类和解相关的不确定税务头寸——是税务判断，不是盈利质量担忧。

**财年说明**：McKesson财年3月31日结束。FY2025 = 2024年4月1日至2025年3月31日。

一、美国药品分销巨头

10-K："We are a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services to help make quality care more accessible and affordable."

McKesson按四个分部报告：

美国药品分部——核心分部，10-K："distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products in the United States. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices."

处方技术解决方案（RxTS）——10-K："combines automation and our ability to navigate the healthcare ecosystem to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to address patients' medication access, affordability, and adherence challenges."

医疗外科解决方案——向包括诊所、手术中心、养老院、医院参考实验室和家庭医疗机构在内的医疗保健提供者分发"医疗外科用品分发、物流和其他服务"。

国际——国际分销运营。

FY2025综合业绩

MD&A：

MD&A："Revenues increased for the year ended March 31, 2025 compared to the prior year largely due to market growth in our U.S. Pharmaceutical segment, including higher volumes largely from retail national account customers and growth in specialty pharmaceuticals."

毛利率压缩

毛利率下降44bp，从4.15%到3.71%。MD&A："Gross profit for the years ended March 31, 2025 and 2024 included gains of $444 million and $244 million, respectively, representing our share of antitrust legal settlements. We recognized these amounts within 'Cost of sales' in the Consolidated Statements of Operations within our U.S. Pharmaceutical segment. Gross profit for the years ended March 31, 2025 and 2024 also included a LIFO charge of $82 million and a credit of $157 million, respectively."

毛利润桥接是微妙的：反垄断和解收益多$2亿，被$2.39亿的LIFO会计波动抵消（从+$1.57亿贷方到-$0.82亿借方）。剔除这些项目，底层毛利率相对稳定。

FY2022-2024的净利润波动反映了大额阿片类诉讼费用和和解。FY2025代表更正常化的基线。

二、现金流：薄利润率业务中的强劲转换

CFFO在16%营收增长下从$43.1亿跳升41%到$60.8亿。FCF $52.3亿很强劲——相当于营收的1.47%，对毛利率低于4%的分销业务来说是优秀的现金吞吐。

负股东权益

McKesson的股东权益连续四年为负，从$-22.7亿略微下降到$-20.7亿。这完全由回购驱动。业务产生大量经常性FCF并激进地返还给股东。归属于McKesson的净利润在FY2025增长10%而稀释每股收益增长15%——5个百分点的差距是股份缩减的增值效应（稀释股数从1.341亿股下降到1.281亿股，下降4.5%）。

三、18项排雷检查

收入质量

三项收入质量检查全部干净通过。仅23天的DSO是医疗保健中最低之一——反映分销的短账单周期和高效营运资本。应收增长略低于营收。CFFO增速近乎营收的3倍。

费用质量

存货增长8.8%落后于COGS增长16.8%——尽管销量更高，存货周转仍改善。SG&A占毛利润63.9%对分销业务来说典型，薄毛利率意味着运营费用消耗较大份额。

现金流质量

C4关注：$56.9亿现金对$73.9亿总债务 = 77%覆盖率。这介于50%失败阈值和100%通过阈值之间。对一家年产$60.8亿CFFO、债务/EBITDA 1.4x的公司来说，覆盖率是舒适的——关注是技术性标记而非压力信号。

资产负债表

债务/EBITDA 1.4x非常健康。商誉+无形占权益的比率在原始数据里显示为"-554%"因为权益为负，使得百分比作为独立度量失去意义。绝对数字是$100亿商誉和$15亿无形资产合计$115亿——相对$751亿总资产基数是可管理的。

并购风险

商誉+无形实际上同比下降6%——反映无形资产的摊销超过任何新增并购活动。

Beneish M-Score

四、10-K原文中的关键风险

1. 法律和监管纠纷（首位风险部分）。 10-K："We experience costly and disruptive legal disputes. We are routinely named as a defendant in litigation or regulatory proceedings and other legal disputes, which may include asserted class action litigation... Regulatory proceedings involve allegations such as false claims, healthcare fraud and abuse, and antitrust violations."

2. 阿片类药物分销诉讼。 10-K："We experience costly legal disputes, government actions, and adverse publicity regarding our role in distributing controlled substances such as opioids. The Company is a defendant in many litigation matters alleging claims related to the distribution of controlled substances (opioids), as described in Financial Note 17, Commitments and Contingent Liabilities."

3. 保险缺口和未保险损失。 "We experience losses not covered by insurance or indemnification. Our business exposes us to risks that are inherent in the distribution, manufacturing, dispensing, and administration of pharmaceuticals and medical-surgical supplies."

4. 医疗欺诈、浪费和滥用监管。 "We are subject to extensive and frequently changing laws relating to healthcare fraud, waste, and abuse."

5. 商誉和无形资产减值风险。 10-K："We might record significant charges from impairment to goodwill, intangibles, and other long-lived assets." 考虑到资产负债表上$115亿的商誉和无形资产，这仍是一个结构性担忧。

6. 阿片类相关的不确定税务头寸（关键审计事项）。 Deloitte："The Company has recorded charges and related tax benefit for opioid-related claims. In order to account for the uncertainty associated with the ultimate realization of the income tax benefit related to opioid-related claims, the Company recorded an uncertain tax position reserve."

五、Altman Z-Score和F-Score

Z-Score 0.62被负的股东权益（Z-Score输入项）人为压低。对一家年产$60.8亿运营现金流、持有投资级信用评级的公司来说，这不是准确反映困境风险。Altman模型是为有正权益的制造商设计的，它错误地为回购重型资本结构打分。

六、总结

评级：A。十七项通过，一项现金对债务的关注反映营运资本管理而非财务压力。

McKesson运营着医疗保健分销板块最干净的运营画像之一：营收增长16%、经营现金流增长41%、自由现金流达$52.3亿、DSO仅23天、存货周转改善、债务/EBITDA健康的1.4x。M-Score -2.48和应计比率-3.7%未显示任何操纵信号。

负的股东权益是主动的资本结构选择：McKesson用自由现金流激进地回购股份（FY2025稀释股数下降4.5%），机械地把权益推到零以下。这是困境的反面——一家对经常性现金流如此有信心的公司，宁愿返还资本而不是在资产负债表上持有现金。77%的现金对债务覆盖关注标记是这一战略的技术性产物；实际债务偿还能力很好。

10-K披露的真正风险是法律和监管：阿片类分销诉讼仍在进行，与阿片类和解相关的不确定税务头寸是Deloitte唯一的关键审计事项，分销模式带有固有的监管风险敞口。盈利质量风险最小；法律和税务风险是管理层关注的或有准备金所在。

财报是起点，不是终点。

⚠️ **免责声明**：本报告基于McKesson 2025 10-K年报原文（SEC EDGAR）及Yahoo Finance公开财务数据，运用排雷框架进行分析，不构成任何投资建议。投资有风险，决策需自行判断。

数据来源：SEC EDGAR 10-K (Filed 2025-05-09) + Yahoo Finance

审计师：Deloitte & Touche LLP（无保留意见，1项关键审计事项）